25 XP   0   0   10

Eliem Therapeutics Inc
Buy, Hold or Sell?

Let's analyze Eliem Therapeutics Inc together

I guess you are interested in Eliem Therapeutics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Eliem Therapeutics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Eliem Therapeutics Inc

I send you an email if I find something interesting about Eliem Therapeutics Inc.

Quick analysis of Eliem Therapeutics Inc (30 sec.)










What can you expect buying and holding a share of Eliem Therapeutics Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
28.6%

What is your share worth?

Current worth
$3.58
Expected worth in 1 year
$3.22
How sure are you?
28.6%

+ What do you gain per year?

Total Gains per Share
$-0.35
Return On Investment
-5.1%

For what price can you sell your share?

Current Price per Share
$6.86
Expected price per share
$3.32 - $11.55
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

1. Valuation of Eliem Therapeutics Inc (5 min.)




Live pricePrice per Share (EOD)

$6.86

Intrinsic Value Per Share

$0.19 - $0.67

Total Value Per Share

$3.77 - $4.24

2. Growth of Eliem Therapeutics Inc (5 min.)




Is Eliem Therapeutics Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$106.3m$130.5m-$21.4m-19.7%

How much money is Eliem Therapeutics Inc making?

Current yearPrevious yearGrowGrow %
Making money-$3.6m-$13.3m$9.6m266.4%
Net Profit Margin0.0%0.0%--

How much money comes from the company's main activities?

3. Financial Health of Eliem Therapeutics Inc (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#345 / 966

Most Revenue
#931 / 966

Most Profit
#370 / 966

Most Efficient
#278 / 966
3rd party ad coffee SUPPORTERis ad-free.

What can you expect buying and holding a share of Eliem Therapeutics Inc? (5 min.)

Welcome investor! Eliem Therapeutics Inc's management wants to use your money to grow the business. In return you get a share of Eliem Therapeutics Inc.

What can you expect buying and holding a share of Eliem Therapeutics Inc?

First you should know what it really means to hold a share of Eliem Therapeutics Inc. And how you can make/lose money.

Speculation

The Price per Share of Eliem Therapeutics Inc is $6.86. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Eliem Therapeutics Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Eliem Therapeutics Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $3.58. Based on the TTM, the Book Value Change Per Share is $-0.09 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.32 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Eliem Therapeutics Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.06-0.8%-0.12-1.8%-0.46-6.7%-0.34-4.9%-0.34-4.9%
Usd Book Value Change Per Share-0.04-0.6%-0.09-1.3%-0.32-4.7%0.263.7%0.263.7%
Usd Dividend Per Share0.000.0%0.000.0%0.030.4%0.020.4%0.020.4%
Usd Total Gains Per Share-0.04-0.6%-0.09-1.3%-0.29-4.3%0.284.1%0.284.1%
Usd Price Per Share2.74-2.72-3.21-4.32-4.32-
Price to Earnings Ratio-12.01--6.61--2.13--7.54--7.54-
Price-to-Total Gains Ratio-67.10--38.01--12.41--25.33--25.33-
Price to Book Ratio0.77-0.74-0.73-0.89-0.89-
Price-to-Total Gains Ratio-67.10--38.01--12.41--25.33--25.33-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share6.86
Number of shares145
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.02
Usd Book Value Change Per Share-0.090.26
Usd Total Gains Per Share-0.090.28
Gains per Quarter (145 shares)-12.7640.57
Gains per Year (145 shares)-51.06162.27
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-51-6114148152
20-102-11228296314
30-153-16342444476
40-204-21457593638
50-255-26571741800
60-306-31685889962
70-357-3679910371124
80-408-41811311851286
90-459-46912713331448
100-511-52014114811610

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.014.00.00.0%0.014.00.00.0%0.014.00.00.0%
Book Value Change Per Share0.04.00.00.0%2.010.00.016.7%4.010.00.028.6%4.010.00.028.6%4.010.00.028.6%
Dividend per Share0.00.04.00.0%4.00.08.033.3%4.00.010.028.6%4.00.010.028.6%4.00.010.028.6%
Total Gains per Share0.04.00.00.0%2.010.00.016.7%4.010.00.028.6%4.010.00.028.6%4.010.00.028.6%
3rd party ad coffee SUPPORTERis ad-free.

Fundamentals of Eliem Therapeutics Inc

About Eliem Therapeutics Inc

Eliem Therapeutics, Inc., a biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. The company was incorporated in 2018 and is headquartered in Wilmington, Delaware.

Fundamental data was last updated by Penke on 2024-06-17 15:48:04.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is cheap.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

1.1. Profitability of Eliem Therapeutics Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Eliem Therapeutics Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Eliem Therapeutics Inc to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Eliem Therapeutics Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--168.0%+168.0%
TTM--209.9%+209.9%
YOY--242.3%+242.3%
5Y--401.7%+401.7%
10Y--532.2%+532.2%
1.1.2. Return on Assets

Shows how efficient Eliem Therapeutics Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Eliem Therapeutics Inc to the Biotechnology industry mean.
  • -1.6% Return on Assets means that Eliem Therapeutics Inc generated $-0.02 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Eliem Therapeutics Inc:

  • The MRQ is -1.6%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -3.2%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-1.6%TTM-3.2%+1.7%
TTM-3.2%YOY-9.9%+6.7%
TTM-3.2%5Y-12.5%+9.3%
5Y-12.5%10Y-12.5%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-1.6%-11.9%+10.3%
TTM-3.2%-11.9%+8.7%
YOY-9.9%-11.3%+1.4%
5Y-12.5%-13.5%+1.0%
10Y-12.5%-14.9%+2.4%
1.1.3. Return on Equity

Shows how efficient Eliem Therapeutics Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Eliem Therapeutics Inc to the Biotechnology industry mean.
  • -1.6% Return on Equity means Eliem Therapeutics Inc generated $-0.02 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Eliem Therapeutics Inc:

  • The MRQ is -1.6%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -3.3%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-1.6%TTM-3.3%+1.7%
TTM-3.3%YOY-10.4%+7.1%
TTM-3.3%5Y-13.6%+10.3%
5Y-13.6%10Y-13.6%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-1.6%-14.2%+12.6%
TTM-3.3%-15.7%+12.4%
YOY-10.4%-14.3%+3.9%
5Y-13.6%-19.2%+5.6%
10Y-13.6%-19.7%+6.1%
3rd party ad coffee SUPPORTERis ad-free.

1.2. Operating Efficiency of Eliem Therapeutics Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Eliem Therapeutics Inc is operating .

  • Measures how much profit Eliem Therapeutics Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Eliem Therapeutics Inc to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Eliem Therapeutics Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--354.6%+354.6%
TTM--225.9%+225.9%
YOY--252.2%+252.2%
5Y--428.3%+428.3%
10Y--531.1%+531.1%
1.2.2. Operating Ratio

Measures how efficient Eliem Therapeutics Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Eliem Therapeutics Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y-0.000
5Y-10Y-0.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-3.004-3.004
TTM-3.332-3.332
YOY-3.502-3.502
5Y-5.271-5.271
10Y-6.915-6.915
3rd party ad coffee SUPPORTERis ad-free.

1.3. Liquidity of Eliem Therapeutics Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Eliem Therapeutics Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 36.70 means the company has $36.70 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Eliem Therapeutics Inc:

  • The MRQ is 36.702. The company is very able to pay all its short-term debts. +2
  • The TTM is 36.488. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ36.702TTM36.488+0.214
TTM36.488YOY20.745+15.744
TTM36.4885Y24.261+12.227
5Y24.26110Y24.2610.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ36.7023.767+32.935
TTM36.4884.000+32.488
YOY20.7454.905+15.840
5Y24.2615.883+18.378
10Y24.2616.286+17.975
1.3.2. Quick Ratio

Measures if Eliem Therapeutics Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Eliem Therapeutics Inc to the Biotechnology industry mean.
  • A Quick Ratio of 36.29 means the company can pay off $36.29 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Eliem Therapeutics Inc:

  • The MRQ is 36.289. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 46.533. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ36.289TTM46.533-10.244
TTM46.533YOY34.051+12.482
TTM46.5335Y33.739+12.794
5Y33.73910Y33.7390.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ36.2893.054+33.235
TTM46.5333.506+43.027
YOY34.0514.756+29.295
5Y33.7395.757+27.982
10Y33.7396.338+27.401
3rd party ad coffee SUPPORTERis ad-free.

1.4. Solvency of Eliem Therapeutics Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Eliem Therapeutics Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Eliem Therapeutics Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.03 means that Eliem Therapeutics Inc assets are financed with 2.7% credit (debt) and the remaining percentage (100% - 2.7%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Eliem Therapeutics Inc:

  • The MRQ is 0.027. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.028. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.027TTM0.028-0.001
TTM0.028YOY0.047-0.019
TTM0.0285Y0.047-0.019
5Y0.04710Y0.0470.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0270.330-0.303
TTM0.0280.342-0.314
YOY0.0470.287-0.240
5Y0.0470.368-0.321
10Y0.0470.382-0.335
1.4.2. Debt to Equity Ratio

Measures if Eliem Therapeutics Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Eliem Therapeutics Inc to the Biotechnology industry mean.
  • A Debt to Equity ratio of 2.8% means that company has $0.03 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Eliem Therapeutics Inc:

  • The MRQ is 0.028. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.029. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.028TTM0.029-0.001
TTM0.029YOY0.049-0.020
TTM0.0295Y0.051-0.022
5Y0.05110Y0.0510.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0280.365-0.337
TTM0.0290.415-0.386
YOY0.0490.370-0.321
5Y0.0510.443-0.392
10Y0.0510.476-0.425
3rd party ad coffee SUPPORTERis ad-free.

2. Market Valuation of Eliem Therapeutics Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Eliem Therapeutics Inc generates.

  • Above 15 is considered overpriced but always compare Eliem Therapeutics Inc to the Biotechnology industry mean.
  • A PE ratio of -12.01 means the investor is paying $-12.01 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Eliem Therapeutics Inc:

  • The EOD is -30.068. Based on the earnings, the company is expensive. -2
  • The MRQ is -12.010. Based on the earnings, the company is expensive. -2
  • The TTM is -6.611. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-30.068MRQ-12.010-18.058
MRQ-12.010TTM-6.611-5.398
TTM-6.611YOY-2.126-4.485
TTM-6.6115Y-7.543+0.931
5Y-7.54310Y-7.5430.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-30.068-2.341-27.727
MRQ-12.010-2.997-9.013
TTM-6.611-2.882-3.729
YOY-2.126-3.553+1.427
5Y-7.543-6.262-1.281
10Y-7.543-6.288-1.255
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Eliem Therapeutics Inc:

  • The EOD is -28.051. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -11.204. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -7.355. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-28.051MRQ-11.204-16.847
MRQ-11.204TTM-7.355-3.849
TTM-7.355YOY-3.004-4.351
TTM-7.3555Y-4.815-2.540
5Y-4.81510Y-4.8150.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-28.051-2.932-25.119
MRQ-11.204-3.739-7.465
TTM-7.355-3.776-3.579
YOY-3.004-4.917+1.913
5Y-4.815-7.942+3.127
10Y-4.815-8.503+3.688
3rd party ad coffee SUPPORTERis ad-free.
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Eliem Therapeutics Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 0.77 means the investor is paying $0.77 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Eliem Therapeutics Inc:

  • The EOD is 1.919. Based on the equity, the company is underpriced. +1
  • The MRQ is 0.766. Based on the equity, the company is cheap. +2
  • The TTM is 0.742. Based on the equity, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD1.919MRQ0.766+1.152
MRQ0.766TTM0.742+0.025
TTM0.742YOY0.733+0.008
TTM0.7425Y0.886-0.144
5Y0.88610Y0.8860.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD1.9191.843+0.076
MRQ0.7662.249-1.483
TTM0.7422.301-1.559
YOY0.7332.412-1.679
5Y0.8863.782-2.896
10Y0.8864.212-3.326
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Eliem Therapeutics Inc.

3.1. Institutions holding Eliem Therapeutics Inc

Institutions are holding 70.566% of the shares of Eliem Therapeutics Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-03-31RA Capital Management, LLC47.43520.45841315084900
2024-03-31BML Capital Management LLC7.91283.96342193742137420.6304
2024-03-31Driehaus Capital Management LLC2.92770.022281168000
2024-03-31Vanguard Group Inc1.1199031048600
2024-03-31Atom Investors LP0.28230.02687827600
2024-03-31Geode Capital Management, LLC0.240306662600
2024-03-31Bridgeway Capital Management, LLC0.19920.00315522300
2024-03-31Northern Trust Corp0.1568043468-5244-10.7653
2024-03-31BlackRock Inc0.1098030440-705-2.2636
2024-03-31Tudor Investment Corp Et AL0.10630.000529466-24-0.0814
2024-03-31State Street Corporation0.078302170000
2024-03-31Millennium Management LLC0.072502010616839.1353
2024-03-31Chicago Partners Investment Group LLC0.04370.001912104-56-0.4605
2024-03-31Renaissance Technologies Corp0.03830.000110617140.132
2024-03-31Advisor Group Holdings, Inc.0.03010.0001833300
2024-03-31UBS Group AG0.02140592559250
2024-03-31Tower Research Capital LLC0.0130.000236061514.3705
2024-03-31Morgan Stanley - Brokerage Accounts0.00620170900
2024-03-31Qube Research & Technologies0.0035098100
2024-03-31Royal Bank of Canada0.00020632775
Total 60.79754.476716855400+15513+0.1%

3.2. Funds holding Eliem Therapeutics Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-04-30Vanguard Total Stock Mkt Idx Inv0.55570.0001165348-24386-12.8527
2024-04-30Vanguard Institutional Extnd Mkt Idx Tr0.40020.000911908300
2024-03-31Bridgeway Ultra-Small Company Market0.17920.07585332300
2024-04-30Fidelity Extended Market Index0.10630.000631637-287-0.899
2024-04-30Fidelity Nasdaq Composite Index0.04920.00071465100
2024-05-30iShares Micro-Cap ETF0.04480.012113316-184-1.363
2024-04-30Fidelity Total Market Index0.0250.0001745200
2024-04-30Fidelity Series Total Market Index0.02430.0001721900
2024-03-31NT Ext Equity Mkt Idx Fd - NL0.01820.0002542300
2024-03-31NT Ext Equity Mkt Idx Fd - L0.0170.0002504900
2024-03-31Northern Trust Extended Eq Market Idx0.0170.0002504900
2024-03-31NT Ext Equity Mkt Idx Fd - DC - NL - T20.01460.0002435820.0459
2024-04-30Spartan Total Market Index Pool E0.01220.0001364200
2024-05-31Dimensional US Core Equity 2 ETF0.00990.0001293729370
2024-05-31State St US Extended Mkt Indx NL Cl C0.00910.0011270000
2023-12-31SSgA U.S. Extended Market Index Class I0.00910.0003270000
2024-04-30Spartan Extended Market Index Pool E0.00660.0005196228717.1343
2024-04-30Vanguard Balanced Index Inv0.00560166900
2024-04-301290 VT Micro Cap K0.00380.0059113700
2024-05-31State St US Ttl Mkt Indx SL Cl I0.00270.000180000
Total 1.51050.0993449455-21631-4.8%
3rd party ad coffee SUPPORTERis ad-free.

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Eliem Therapeutics Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.041-0.088+116%-0.322+688%0.255-116%0.255-116%
Book Value Per Share--3.5763.665-2%4.388-19%3.914-9%3.914-9%
Current Ratio--36.70236.488+1%20.745+77%24.261+51%24.261+51%
Debt To Asset Ratio--0.0270.028-4%0.047-43%0.047-43%0.047-43%
Debt To Equity Ratio--0.0280.029-4%0.049-44%0.051-45%0.051-45%
Dividend Per Share----0%0.029-100%0.024-100%0.024-100%
Eps---0.057-0.122+114%-0.457+700%-0.336+489%-0.336+489%
Free Cash Flow Per Share---0.061-0.0610%-0.351+474%-0.244+299%-0.244+299%
Free Cash Flow To Equity Per Share---0.061-0.054-12%-0.380+526%0.187-132%0.187-132%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--0.669--------
Intrinsic Value_10Y_min--0.191--------
Intrinsic Value_1Y_max---0.845--------
Intrinsic Value_1Y_min---0.831--------
Intrinsic Value_3Y_max---1.845--------
Intrinsic Value_3Y_min---1.775--------
Intrinsic Value_5Y_max---2.006--------
Intrinsic Value_5Y_min---1.921--------
Market Cap204100778.000+60%81521302.00080851875.250+1%95356121.500-15%128614942.571-37%128614942.571-37%
Net Profit Margin----0%-0%-0%-0%
Operating Margin----0%-0%-0%-0%
Operating Ratio----0%-0%-0%-0%
Pb Ratio1.919+60%0.7660.742+3%0.733+4%0.886-13%0.886-13%
Pe Ratio-30.068-150%-12.010-6.611-45%-2.126-82%-7.543-37%-7.543-37%
Price Per Share6.860+60%2.7402.718+1%3.205-15%4.323-37%4.323-37%
Price To Free Cash Flow Ratio-28.051-150%-11.204-7.355-34%-3.004-73%-4.815-57%-4.815-57%
Price To Total Gains Ratio-167.984-150%-67.096-38.013-43%-12.408-82%-25.328-62%-25.328-62%
Quick Ratio--36.28946.533-22%34.051+7%33.739+8%33.739+8%
Return On Assets---0.016-0.032+107%-0.099+538%-0.125+706%-0.125+706%
Return On Equity---0.016-0.033+107%-0.104+551%-0.136+751%-0.136+751%
Total Gains Per Share---0.041-0.088+116%-0.293+616%0.280-115%0.280-115%
Usd Book Value--106384000.000109056500.000-2%130542250.000-19%116464214.286-9%116464214.286-9%
Usd Book Value Change Per Share---0.041-0.088+116%-0.322+688%0.255-116%0.255-116%
Usd Book Value Per Share--3.5763.665-2%4.388-19%3.914-9%3.914-9%
Usd Dividend Per Share----0%0.029-100%0.024-100%0.024-100%
Usd Eps---0.057-0.122+114%-0.457+700%-0.336+489%-0.336+489%
Usd Free Cash Flow---1819000.000-1810250.0000%-10441750.000+474%-7248785.714+299%-7248785.714+299%
Usd Free Cash Flow Per Share---0.061-0.0610%-0.351+474%-0.244+299%-0.244+299%
Usd Free Cash Flow To Equity Per Share---0.061-0.054-12%-0.380+526%0.187-132%0.187-132%
Usd Market Cap204100778.000+60%81521302.00080851875.250+1%95356121.500-15%128614942.571-37%128614942.571-37%
Usd Price Per Share6.860+60%2.7402.718+1%3.205-15%4.323-37%4.323-37%
Usd Profit---1697000.000-3631500.000+114%-13304750.000+684%-10240285.714+503%-10240285.714+503%
Usd Revenue----0%-0%-0%-0%
Usd Total Gains Per Share---0.041-0.088+116%-0.293+616%0.280-115%0.280-115%
 EOD+5 -3MRQTTM+17 -12YOY+21 -105Y+16 -1510Y+16 -15

4.2. Fundamental Score

Let's check the fundamental score of Eliem Therapeutics Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-30.068
Price to Book Ratio (EOD)Between0-11.919
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than136.289
Current Ratio (MRQ)Greater than136.702
Debt to Asset Ratio (MRQ)Less than10.027
Debt to Equity Ratio (MRQ)Less than10.028
Return on Equity (MRQ)Greater than0.15-0.016
Return on Assets (MRQ)Greater than0.05-0.016
Total4/10 (40.0%)

4.3. Technical Score

Let's check the technical score of Eliem Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5042.135
Ma 20Greater thanMa 507.904
Ma 50Greater thanMa 1007.674
Ma 100Greater thanMa 2005.324
OpenGreater thanClose6.760
Total3/5 (60.0%)



Latest Balance Sheet

Balance Sheet of 2024-03-31. Currency in USD. All numbers in thousands.

Summary
Total Assets109,334
Total Liabilities2,950
Total Stockholder Equity106,384
 As reported
Total Liabilities 2,950
Total Stockholder Equity+ 106,384
Total Assets = 109,334

Assets

Total Assets109,334
Total Current Assets108,271
Long-term Assets1,063
Total Current Assets
Cash And Cash Equivalents 105,031
Net Receivables 2,021
Other Current Assets 1,219
Total Current Assets  (as reported)108,271
Total Current Assets  (calculated)108,271
+/-0
Long-term Assets
Property Plant Equipment 111
Long-term Assets Other 952
Long-term Assets  (as reported)1,063
Long-term Assets  (calculated)1,063
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities2,950
Long-term Liabilities0
Total Stockholder Equity106,384
Total Current Liabilities
Short-term Debt 225
Accounts payable 85
Other Current Liabilities 2,725
Total Current Liabilities  (as reported)2,950
Total Current Liabilities  (calculated)3,035
+/- 85
Long-term Liabilities
Long-term Liabilities  (as reported)0
Long-term Liabilities  (calculated)0
+/-0
Total Stockholder Equity
Common Stock3
Retained Earnings -157,676
Other Stockholders Equity 264,057
Total Stockholder Equity (as reported)106,384
Total Stockholder Equity (calculated)106,384
+/-0
Other
Capital Stock3
Cash and Short Term Investments 105,031
Common Stock Shares Outstanding 27,639
Current Deferred Revenue-85
Liabilities and Stockholders Equity 109,334
Net Debt -104,806
Net Invested Capital 106,384
Net Working Capital 106,273
Property Plant and Equipment Gross 111
Short Long Term Debt Total 225



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-31
> Total Assets 
0
0
0
24,631
53,686
107,627
182,251
173,241
162,419
150,105
140,858
134,992
122,085
116,274
112,735
110,469
109,334
109,334110,469112,735116,274122,085134,992140,858150,105162,419173,241182,251107,62753,68624,631000
   > Total Current Assets 
0
0
0
21,998
52,537
104,803
158,632
148,252
133,283
133,076
133,171
134,393
109,372
114,244
112,434
110,255
108,271
108,271110,255112,434114,244109,372134,393133,171133,076133,283148,252158,632104,80352,53721,998000
       Cash And Cash Equivalents 
0
0
0
20,487
47,911
99,482
62,819
46,922
31,931
32,602
35,944
43,585
34,437
25,294
57,353
93,112
105,031
105,03193,11257,35325,29434,43743,58535,94432,60231,93146,92262,81999,48247,91120,487000
       Short-term Investments 
0
0
0
0
0
0
83,199
89,558
92,010
90,349
86,675
79,981
74,935
77,339
50,080
13,686
0
013,68650,08077,33974,93579,98186,67590,34992,01089,55883,199000000
       Net Receivables 
0
0
0
0
2,535
2,541
6,943
6,523
6,523
5,851
5,066
6,492
6,587
6,865
1,922
2,024
2,021
2,0212,0241,9226,8656,5876,4925,0665,8516,5236,5236,9432,5412,5350000
       Other Current Assets 
0
0
0
11
608
458
1,050
852
600
1,102
555
10,827
621
629
601
1,433
1,219
1,2191,43360162962110,8275551,1026008521,05045860811000
   > Long-term Assets 
0
0
0
2,633
1,149
2,824
23,619
24,989
29,136
17,029
7,687
599
12,713
2,030
301
214
1,063
1,0632143012,03012,7135997,68717,02929,13624,98923,6192,8241,1492,633000
       Property Plant Equipment 
0
0
0
0
0
0
0
0
807
697
585
471
662
372
286
199
111
11119928637266247158569780700000000
       Long Term Investments 
0
0
0
0
0
0
23,619
24,919
25,911
11,701
6,961
0
0
0
0
0
0
0000006,96111,70125,91124,91923,619000000
       Other Assets 
0
0
0
0
1,149
2,824
0
70
2,418
4,631
141
128
0
1,658
0
0
0
0001,65801281414,6312,4187002,8241,1490000
> Total Liabilities 
0
0
0
3,063
4,070
5,713
5,590
6,038
7,277
7,870
6,499
6,277
5,225
3,773
2,993
2,870
2,950
2,9502,8702,9933,7735,2256,2776,4997,8707,2776,0385,5905,7134,0703,063000
   > Total Current Liabilities 
0
0
0
3,063
4,070
5,713
5,590
6,031
6,896
7,614
6,280
6,097
4,915
3,618
2,901
2,833
2,950
2,9502,8332,9013,6184,9156,0976,2807,6146,8966,0315,5905,7134,0703,063000
       Short-term Debt 
0
0
0
0
0
0
0
0
459
439
352
300
464
485
401
334
225
22533440148546430035243945900000000
       Accounts payable 
0
0
0
1,086
2,003
1,955
2,579
1,404
847
1,061
1,494
750
864
878
736
66
85
85667368788647501,4941,0618471,4042,5791,9552,0031,086000
       Other Current Liabilities 
0
0
0
1,977
2,067
3,758
3,011
4,627
5,590
6,114
4,434
5,047
3,587
2,255
1,764
2,499
2,725
2,7252,4991,7642,2553,5875,0474,4346,1145,5904,6273,0113,7582,0671,977000
   > Long-term Liabilities 
0
0
0
0
0
0
0
7
381
256
219
180
310
155
92
37
0
0379215531018021925638170000000
       Warrants
0
0
0
0
0
152,759
0
0
0
0
0
0
0
0
0
0
0
00000000000152,75900000
       Other Liabilities 
0
0
0
0
0
0
0
7
0
0
0
0
0
55
0
0
0
000550000070000000
> Total Stockholder Equity
0
0
0
21,568
49,616
101,914
176,661
167,203
155,142
142,235
134,359
128,715
116,860
112,501
109,742
107,599
106,384
106,384107,599109,742112,501116,860128,715134,359142,235155,142167,203176,661101,91449,61621,568000
   Common Stock
0
0
0
1
1
1
3
3
3
3
3
3
3
3
3
3
3
33333333333111000
   Retained Earnings Total Equity0000-143,150-120,860-113,0980-88,820-75,616-65,071-55,45600000
   Accumulated Other Comprehensive Income 0-2-11-35-95-358-581-604-521-123-18000000
   Capital Surplus 
0
0
0
0
0
4,610
241,747
242,939
244,480
0
248,035
249,930
260,102
0
0
0
0
0000260,102249,930248,0350244,480242,939241,7474,61000000
   Treasury Stock00000000000000000
   Other Stockholders Equity 
0
0
0
3,152
3,554
4,610
59,496
242,939
244,480
246,252
248,035
249,930
260,102
260,903
262,088
263,577
264,057
264,057263,577262,088260,903260,102249,930248,035246,252244,480242,93959,4964,6103,5543,152000



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue0
Cost of Revenue-0
Gross Profit00
 
Operating Income (+$)
Gross Profit0
Operating Expense-40,275
Operating Income-40,275-40,275
 
Operating Expense (+$)
Research Development15,411
Selling General Administrative9,888
Selling And Marketing Expenses24,854
Operating Expense40,27550,153
 
Net Interest Income (+$)
Interest Income4,620
Interest Expense-0
Other Finance Cost-0
Net Interest Income4,620
 
Pretax Income (+$)
Operating Income-40,275
Net Interest Income4,620
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-35,119-45,431
EBIT - interestExpense = -61,741
-35,140
-35,119
Interest Expense0
Earnings Before Interest and Taxes (EBIT)-61,741-35,119
Earnings Before Interest and Taxes (EBITDA)-40,275
 
After tax Income (+$)
Income Before Tax-35,119
Tax Provision-0
Net Income From Continuing Ops-39,240-35,119
Net Income-35,119
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses40,275
Total Other Income/Expenses Net5,156-4,620
 

Technical Analysis of Eliem Therapeutics Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Eliem Therapeutics Inc. The general trend of Eliem Therapeutics Inc is BULLISH with 57.1% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Eliem Therapeutics Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (57.1%) Bearish trend (-57.1%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Eliem Therapeutics Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 7.025 < 9.58 < 11.55.

The bearish price targets are: 5.19 > 3.42 > 3.32.

Tweet this
Eliem Therapeutics Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Eliem Therapeutics Inc. The current mas is .

The long score for the Moving Averages is 11/14.
The longshort score for the Moving Averages is 8/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Eliem Therapeutics Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Eliem Therapeutics Inc. The current macd is -0.18681266.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Eliem Therapeutics Inc price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Eliem Therapeutics Inc. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Eliem Therapeutics Inc price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Eliem Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) ChartEliem Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Eliem Therapeutics Inc. The current adx is 21.82.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -1/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Eliem Therapeutics Inc shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Eliem Therapeutics Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Eliem Therapeutics Inc. The current sar is 8.2837431.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Eliem Therapeutics Inc Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Eliem Therapeutics Inc. The current rsi is 42.14. The current phase is Correction in bull market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is -2/(-13 +13).

  • Correction in bull market: Moderate price decline, potential pause in the uptrend. Reassess the market, wait for signs of stabilization.
  • Trending up: The RSI is trending up. +1
Eliem Therapeutics Inc Daily Relative Strength Index (RSI) ChartEliem Therapeutics Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Eliem Therapeutics Inc. The current phase is Oversold in bull market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 0/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Eliem Therapeutics Inc price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Eliem Therapeutics Inc Daily Stochastic Oscillator ChartEliem Therapeutics Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Eliem Therapeutics Inc. The current cci is -136.07319941.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
Eliem Therapeutics Inc Daily Commodity Channel Index (CCI) ChartEliem Therapeutics Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Eliem Therapeutics Inc. The current cmo is -24.92179468.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Eliem Therapeutics Inc Daily Chande Momentum Oscillator (CMO) ChartEliem Therapeutics Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Eliem Therapeutics Inc. The current willr is -89.17910448.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Eliem Therapeutics Inc Daily Williams %R ChartEliem Therapeutics Inc Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Eliem Therapeutics Inc.

Eliem Therapeutics Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Eliem Therapeutics Inc. The current atr is 0.8145822.

Eliem Therapeutics Inc Daily Average True Range (ATR) ChartEliem Therapeutics Inc Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Eliem Therapeutics Inc. The current obv is 45,647,329.

Eliem Therapeutics Inc Daily On-Balance Volume (OBV) ChartEliem Therapeutics Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Eliem Therapeutics Inc. The current mfi is 40.99.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Eliem Therapeutics Inc Daily Money Flow Index (MFI) ChartEliem Therapeutics Inc Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Eliem Therapeutics Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-02-12DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-14STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-16STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-21SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-22MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-27STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-02-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-04STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-03-05BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-03-08SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-11STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-03-12MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-13MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-14CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-15MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-18MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-19DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-03-20STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-21CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-22DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-25STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-26MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-27STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-28CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-01MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-02DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-04-03STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-04-04SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-04-05MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-10DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-11MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-04-15WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-16STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-18RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-04-24MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-25SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-04-26STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-29MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-30WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-05-02ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-05-03STOCH LONG EXITThe %K line crosses below the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-05-06ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-05-07STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-05-08RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-05-15MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-05-16SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-05-20MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-05-21WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-05-23CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-05-24STOCH SHORT EXITThe %K line crosses above the %D line.
2024-05-28CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-05-29MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-05-30MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-06-05SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-06-06STOCH LONG EXITThe %K line crosses below the %D line.
2024-06-07STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-06-10STOCH LONG EXITThe %K line crosses below the %D line.
2024-06-12STOCH SHORT EXITThe %K line crosses above the %D line.
2024-06-14CCI LONG ENTRY SHORT CLOSE100 crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-06-17STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-06-18SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-06-20STOCH SHORT EXITThe %K line crosses above the %D line.
2024-06-21CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-06-24STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-06-25CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-06-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-06-28DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-07-01CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-07-03STOCH SHORT EXITThe %K line crosses above the %D line.

6.3. Candlestick Patterns

Eliem Therapeutics Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Eliem Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5042.135
Ma 20Greater thanMa 507.904
Ma 50Greater thanMa 1007.674
Ma 100Greater thanMa 2005.324
OpenGreater thanClose6.760
Total3/5 (60.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Eliem Therapeutics Inc with someone you think should read this too:
  • Are you bullish or bearish on Eliem Therapeutics Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Eliem Therapeutics Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Eliem Therapeutics Inc

I send you an email if I find something interesting about Eliem Therapeutics Inc.


Stay informed about Eliem Therapeutics Inc.

Receive notifications about Eliem Therapeutics Inc in your mailbox!